The drug Prolanta or G129R has been researched and studied by its inventor, Wen Chen, who is also an advisor to Oncolix, since 1999: https://www.ncbi.nlm.nih.gov/pubmed/10589775
ITOR/GHS is where they are doing their clinical trials, note that they are one of the highlighted companies along side Amgen, AstraZeneca, Eisai Pharmaceuticals, and Novartis: http://www.itor-ghs.org/pharmaceutical-industry.php
Also, in that S-1/A filing, those shares are being distributed to all of the owners and investors of Oncolix when the company was private. Oncolix is more than 70% institutional ownership. Greenville Health System, Texas Treasury Safekeeping Trust, Biovectra, Integrium. The most recent financing in that S-1/A is a private placement with companies Newbridge Securities Corporation and LifeTech Capital.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.